Contact Us

Cox-II Inhibitors
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Which Cox II Inhibitor(s) did you take?

Date you started taking this drug:

Date you stopped taking this drug:

Have any of the following side effects occurred? (Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

SEC Asks For Pfizer Documents

Aug 9, 2005 | Bloomberg News

Pfizer Inc., the world's biggest drugmaker, said the Securities and Exchange Commission has requested documents about its Cox-2 class of painkillers.

In its quarterly filing submitted to the regulator today, the company didn't say when the SEC made its request. New York-based Pfizer earlier received a similar request from the U.S. Justice Department.

In April, the drugmaker suspended sales of Bextra, a Cox-2 painkiller in the same class as Merck & Co.'s Vioxx, which was withdrawn Sept. 30 because of an increased risk of heart attack and stroke in users.

The Food and Drug Administration asked Pfizer to include heart risks on the label of arthritis drug Celebrex.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo